Intracellular Magnesium and Heart Failure

Heart Failure With Preserved Ejection Fraction Clinical Trial

Official title:

Exploring Intramyocellular Magnesium Augmentation: Implications for Myocardial and Skeletal Muscle Metabolism in Individuals With Heart Failure With Preserved Ejection Fraction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06353750
• Other study ID #: 331039
• Status: Not yet recruiting
• Start date: April 15, 2024
• Est. completion date: April 25, 2026

Study information

• Verified date: March 2024
• Source: University of Oxford
• Contact: Jennifer L Holland, BMBS
• Phone: 01865 221172
• Email: jennifer.holland[@]wolfson.ox.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Low magnesium levels are surprisingly common in those with a heart condition known as HFpEF, where the heart pumps well but is too rigid to fill properly with blood. While routine blood tests can check magnesium levels, they don't tell us how much magnesium is actually inside the heart and muscle cells, where it's vital for energy and overall function. Our research aims to get a clearer picture by looking directly at the magnesium inside these cells and understanding its role in the body's energy production and usage. We're also interested in how magnesium levels affect symptoms and the body's handling of sugar. We're using advanced medical imaging techniques, like heart magnetic resonance imaging (MRI) and other heart and muscle function tests, at rest and when the heart is working hard to help answer these questions. We'll compare the magnesium levels inside the cells before and after giving a supplement of magnesium to see if this can make a difference in how the heart and muscles work.

Description:

Hypomagnesaemia is prevalent among patients suffering from heart failure with preserved ejection fraction (HFpEF), and in those with predisposing risk factors such as obesity and diabetes. The intricate link between hypomagnesaemia and the pathophysiological processes of HFpEF remains to be fully elucidated. However, its notable prevalence suggests a significant role in the onset and advancement of the disease. Serum magnesium (S-Mg) is commonly used to evaluate Mg status, however, it does not accurately reflect true intracellular Mg concentrations ([Mg2+]i), where this essential ion exerts its beneficial effects. Thus, previous literature lacks a thorough evaluation of [Mg2+]i in HFpEF, and specifically the potential impact of Mg replete physiology. The research hypothesis is that [Mg2+]i is related to myocardial and skeletal muscle (SM) energetics and performance in patients with HFpEF. The study aims to explore the role of [Mg2+]i at a functional and cellular level in cardiac and SM, symptomatology, and insulin sensitivity; comparing a HFpEF population with healthy and matched controls. Using the chemical shift difference in the resonance frequencies of the α- and β- phosphate resonances in magnetic resonance spectroscopy (MRS), [Mg2+]i will be measured, comparing it to S-Mg. Blood samples for cardiac biomarkers, electrolytes, and markers of HFpEF risk factors (such as lipid profile, HbA1C and TSH) will be taken and a calf leg raise performed. Advanced imaging techniques at rest and stress including cardiac magnetic resonance imaging (CMR), MRS and echocardiography will be performed. MRS measurements include cellular energetics (Phosphocreatine [PCr]/ATP), rate of myocardial ATP delivery (CK flux and KfCK) and skeletal muscle energetics (PCr recovery Tau). At two time points post-Mg augmentation (immediate and delayed [7-15 days]), investigations will be repeated. This study aspires to quantify [Mg2+]i in the HFpEF population compared with healthy and matched controls, juxtapose its levels with S-Mg, and examine its significance in the pathophysiology, functional and cellular performance, and symptom presentation of HFpEF. The study aims to recruit 45 individuals with HFpEF, 20 healthy controls and 20 age-and sex-matched individuals over a 2-year period.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 85
• Est. completion date: April 25, 2026
• Est. primary completion date: February 28, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria

• Participant is willing and able to give informed consent for participation in the study.
• Participant aged at least 18 years old. 6.2.2 Additional inclusion criteria for participants in the HFpEF arm
• Clinical diagnosis of HFpEF
• HFA-PEFF score = 5 6.2.3 Additional inclusion criteria for participants in the healthy and matched control arm
• HFA-PEFF < 3
• No known diagnosis of heart failure 6.3 Exclusion criteria
• Participant is unwilling or unable to give informed consent
• Any impediment to communication which, in the opinion of the investigator, might prevent the investigator communicating effectively with the patient during the study which could cause a safety or reliability concern.
• Any other condition which, in the opinion of the investigator, might affect the safety of the participant or reduce the reliability of the study results
• Involvement in any other research project where the procedures would affect the outcomes of this study.
• Individuals with NYHA class IV symptoms
• Known ischaemic heart disease, ICD, or CRT in situ.
• Individuals on oral magnesium supplementation
• Insulin dependent diabetes
• Standard contraindications to magnetic resonance imaging (MRI), (Metal clips or metallic foreign body, prior injury to the eye involving fragments of metal, prior shrapnel injuries, any other metallic or electronic implants affected by the magnetic field, history of severe claustrophobia, history of chronic kidneys disease, egg, or soya allergy)
• Heart transplant recipient
• Cardiomyopathy from infiltrative or storage diseases, muscular dystrophies, or with reversible causes, hypertrophic cardiomyopathy
• Moderate or greater valvular heart disease
• Acute HF requiring iv diuretics, inotropes, vasodilators, or hospitalisation within 6 weeks of screening
• BMI>40kg/m2 (due to MRS sensitivity).
• Pregnancy (due to magnesium infusion).
• Chronic kidney disease stage 4/5 (due to contrast injection)

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure With Preserved Ejection Fraction
• Hypomagnesemia

Intervention

Other:
• Magnesium supplement
Intravenous magnesium supplement (10mmol).

Locations

Country	Name	City	State
United Kingdom	Oxford Centre for Magnetic Resonance (OCMR)	Oxford

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	British Heart Foundation, Oxford University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Myocardial/ skeletal muscle metabolism and energetics at rest and stress.	Measuring myocardial metabolism (PCr/ATP, CK flux and KfCK, PDH flux), and skeletal muscle metabolism (PCr recovery Tau) at rest and stress. Measurements at three time points (pre-Mg infusion, immediately post and delayed (7-15 days) after Mg infusion, comparing HFpEF population with healthy and matched controls.	7-15 days
Secondary	Serum versus intracellular magnesium concentration	Comparing serum magnesium with intracellular magnesium concentrations using MRS, at all time points (pre-Mg infusion, and post (immediately and 7-15 days after) Mg infusion).	7-15 days
Secondary	Cardiac function	Comparing systolic and diastolic function (echocardiography) at rest and exercise at the three time points (pre-Mg infusion, immediately post and delayed (7-15 days) after Mg infusion), and assessing if [Mg2+] has a stronger correlation with cardiac function than serum Mg2+.	7-15 days
Secondary	Skeletal muscle performance	Comparing Calf raise test at the three time points (pre-Mg infusion, immediately post and delayed (7-15 days) after Mg infusion), and assessing if [Mg2+] has a stronger correlation with test performance than serum Mg2+.	7-15 days
Secondary	Symptoms	To assess if Mg2+ infusion affects perceived exercise tolerance (NYHA class and symptom questionnaire) at 2 time points (pre-Mg infusion, and 7-15 days post-Mg infusion).	7-15 days
Secondary	Insulin sensitivity	To assess if Mg2+ infusion affects a HOMA-IR score (based on fasted serum glucose and insulin levels).; To assess if Mg2+ infusion affects a HOMA-IR score (based on fasted serum glucose and insulin levels).; To assess if Mg2+ infusion affects a HOMA-IR score (based on fasted serum glucose and insulin levels).; To assess if Mg2+ infusion affects a HOMA-IR score (based on fasted serum glucose and insulin levels), comparing 2 time points (pre-Mg infusion, and 7-15 days post-Mg infusion).	7-15 days